Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) exchanged hands 62,148,600 shares versus average trading capacity of 9.59M shares, while its relative trading volume is 7.14. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s total market worth is $7.95B along with 194.20M outstanding shares.

Insiders has most recently took part in a trading activity, Bollag Daniel M, Sr. VP, Reg. Affairs & Quality of the company in a transaction that occurred 1/9/2017 sold 32,000 shares of the stock. The stock was sold at a price of $23.78, for a total value of $760,960. Subsequent to the transaction Bollag Daniel M owned a total of 129,404 shares of the stock.

In a separate transaction on 10/24/2016, Clackson Timothy P, President, R&D, CSO sold 19,638 shares of the stock. The stock was sold at a price of $9.56, for a total worth of $187,739. Succeeding to the transaction Clackson Timothy P owned overall 197,884 shares of the stock.

Moreover, Bollag Daniel M, Sr. VP, Reg. Affairs & Quality sold 47,384 shares of the stock in a reserved transaction that ensued on 10/3/2016. At a price of $13.46, the stock was sold for an entire value of $637,812. Consequent to the transaction Bollag Daniel M owned a total of 129,404 shares of the stock.

Currently, 0.20% shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) are owned by insiders with -39.75% six-month change in the insider ownership. The insider filler data counts the number of monthly positions over 3 month and 12 month time spans. For Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) total 1 number of trades held during last 3 months and 62 during last 12 months, out of them 0 numbers of buys held in last 3 months and 10 buys in last 12 months. Whereas 1 numbers of sells held in last 3 months and 52 sells over the past 12 months.

For the duration of last three months Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s total number of shares bought are 0 and sold 19,638 from a total of 19,638 traded shares. During last twelve months 199,491 number of shares bought and 895,484 sold from a total of 1,094,975 shares traded. A net activity of 19,638 took place in the course of three months, while 695,993 during last twelve months. Insider trading information is derived from Forms 3 and 4 filings are filed with the U.S. Securities and Exchange Commission (SEC).

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) ended last trading session at the price of $23.68 whereas a number of traders indicating mean target price will hit $20.38 over the next twelve months, mean value of price target most recently revised on 01/10/17. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s highest estimates of price target are $24.00 and low forecast is $14.00 based on the opinion of 8 analysts. The price target estimates represents a standard deviation of 6.28. However brokerage recommendations suggests an ABR of 2.00 based on calls of 8 experts.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is expected to release the earnings of its current quarter on 2/28/17. The company is expected to release $-0.18 EPS during current quarter according to 9 analysts whereas the company reported $-0.32 EPS during same quarter a year ago. For the current quarter the stock has a lowest EPS estimates of $-0.21 and high estimate of $-0.12. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s average revenue estimates for the current quarter are $45.61M according to 10 number of analysts. However its lowest revenue estimates are $42.5M and highest revenue estimates are $58.8M. A year ago the company’s sales were $36.51M. Its yearly sales growth estimates are 24.90%.Ffor the next five years the analysts that follow this company are expecting its growth at -25.54%.